Hangzhou Tigermed Consulting Co., Ltd. Class A · SZSE:300347
Hangzhou Tigermed Consulting Co., Ltd. Class A — H1 2026 Earnings Presentation
34 slides from Hangzhou Tigermed Consulting Co., Ltd. Class A's earnings presentation, August 2026
Slide 1: 2026 Interim Results
2026 Interim Results Hangzhou Tigermed Consulting Co., Ltd. 300347.SZ / 3347.HK August 2026 www.tigermedgrp.com
Slide 2: Disclaimer
Disclaimer This document is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2026 interim results announcement and other relevant announcements published on the websites of the Shenzhen Stock Exchange (
Slide 3: Interim Results Overview
01 Interim Results Overview www.tigermedgrp.com
Slide 4: Continued Recovery in 2Q2026 Results
Continued Recovery in 2Q2026 Results Adjusted Net Profit Attributable to the Owners of Revenue Gross Profit and Margin the Company and Margin (1) (RMB mm) (RMB mm) (RMB mm) 26.6% 28.4% 6.7% 8.3% +5.8% +12.6% +30.6% 1,906.1 1,801.5 157.3 540.6 479.9 120.4 1Q2026 2Q2026 1Q2026 2Q2026 1Q2026 2Q2026 (1)
Slide 5: 1H2026 Key Financials
1H2026 Key Financials Adjusted Net Profit Attributable to the Owners of Revenue Gross Profit and Margin the Company and Margin (1) (RMB mm) (RMB mm) (RMB mm) 30.1% 27.5% 6.5% 7.5% +14.1% +4.3% +31.8% 3,707.6 3,250.4 1,934.2 978.0 1,020.5 1,780.9 277.7 642.8 646.4 210.7 1,773.4 1,469.5 335.2 374.1 1H
Slide 6: Revenue Breakdown by China and Overseas Markets
Revenue Breakdown by China and Overseas Markets China Revenue Overseas Revenue Revenue Breakdown by Region (RMB mm) (RMB mm) 57% 1H2026 43% +24.0% +3.2% 2,106.1 China Overseas 1,697.9 1,601.5 1,552.5 48% 1H2025 52% 1H2025 1H2026 1H2025 1H2026 China Overseas 6
Slide 7: Cost of Services
Cost of Services Cost of Services Breakdown by Nature and as % of Revenue (RMB mm) 69.9% 72.5% +18.2% 2,687.1 2,272.5 8.2% 9.4% 27.2% 22.6% 37.9% 37.1% 1H2025 1H2026 Direct labor costs Direct project-related costs Overhead costs 7
Slide 8: Operating Expenses
Operating Expenses Selling and Marketing Expenses Administrative Expenses R&D Expenses Share-based Compensation and as % of Revenue and as % of Revenue and as % of Revenue and as % Revenue (RMB mm) (RMB mm) (RMB mm) (RMB mm) 3.3% 3.0% 10.9% 9.5% 3.9% 3.8% 0.3% 0.1% +1.7% -0.6% +9.8% -54.4% 107.9 109
Slide 9: Business Updates: Clinical Trial Solutions (CTS)
02 Business Updates Clinical Trial Solutions (“CTS”) www.tigermedgrp.com
Slide 10: Clinical Trial Solutions (CTS)
Clinical Trial Solutions (“CTS”) Segment Revenue Segment Gross Profit and Margin (RMB mm) (RMB mm) 22.8% 21.1% +20.7% +11.6% 1,773.4 1,469.5 374.1 335.2 1H2025 1H2026 1H2025 1H2026 10
Slide 11: CTS Key Business Updates
CTS Key Business Updates Number of Ongoing Drug Clinical Research Number of Ongoing Drug Clinical Research Projects by Phase(1) Projects by Region(1) 663 667 663 667 646 646 48 55 106 86 43 95 14 39 15 194 193 209 144 140 140 116 119 128 409 422 403 276 284 274 06/30/2025 12/31/2025 06/30/2026 06/30
Slide 12: Global Clinical Operation Business Updates
Global Clinical Operation Business Updates 11,984 global employees across 43 countries, including 2,019 overseas Number of Ongoing Overseas Drug Clinical employees Research Projects (1) Established a subsidiary in New Zealand to expand service scope and capabilities in Australia and the Asia-Pacific
Slide 13: Global Clinical Operation Business Updates (Cont'd)
Global Clinical Operation Business Updates (Cont’d) North America ⚫ As of June 30, 2026, 59 ongoing clinical trial projects in the U.S., up 45% YoY, with multiple successful FDA inspections ⚫ In H1 2026, U.S. clinical team exceeded 200 people; 46 new contracts signed, including 16 clinical operation
Slide 14: H1 2026: Robust Funding Activities and Rising Innovation Influence
H1 2026: Robust Funding Activities and Rising Innovation Influence Out-licensing Surge with Enhanced A Bottoming-Out Rebound of Funding to the Partnership Models Industry • H1 2026 upfront payments from out-licensing deals approached $5 • Primary market financing reached $ 4.26 billion, up 189% YoY(
Slide 15: Total Financing and Upfront Payments Hit a 5-Year High
Total Financing and Upfront Payments Hit a 5-Year High China’s innovative drug industry financing + upfront payments in H1 2026 reached $ 9.22 billion, surpassing USD 8.485 billion in H1 2021 China’s Innovative Drug Industry PE/VC Financing and Out-Licensing Upfront Payments ($100M) Financing Upfron
Slide 16: Tigermed Ranks Second Among CROs for Overseas Sponsors' China Projects
Tigermed Ranks Second Among CROs for Overseas Sponsors’ China Projects 90 From 2025 to H1 2026, multinational clinical CROs dominated overseas sponsors’ China clinical projects registered with HGRAC; Tigermed ranked first among domestic CROs 2026H1 2025 29 37 35 4 61 15 22 12 15 15 31 13 22 5 7 10 1
Slide 17: H1 2026 Corporate Highlight: Strengthening Foundations and Expanding the Ecosystem
H1 2026 Corporate Highlight: Strengthening Foundations and Expanding the Ecosystem In H1 2026, signed strategic cooperation In March 2026, Tigermed’s new global In H1 2026, completed the acquisitions of agreements with Hisun Pharmaceutical, headquarters building and Tigermed Park Teddy Laboratory an
Slide 18: CTS Key Business Updates
CTS Key Business Updates Regulatory Affairs (“RA”) ⚫ As of June 30, 2026, cumulative RA projects experience reached 1,640. Added 28 new U.S. FDA IND projects in H1 2026, of which 21 have received FDA clinical trial approvals ⚫ In H1 2026, assisted 5 products commercially approved in China; 69 IND/MR
Slide 19: CTS Key Business Updates (Cont'd)
CTS Key Business Updates (Cont’d) Pharmacovigilance (“PV”) ⚫ In H1 2026, added 141 new projects, up 17% YoY; added 109 new clients, up 25% YoY ⚫ Global pharmacovigilance team exceeded 200 people, with presence in the U.S., Europe, Japan, Southeast Asia, South Korea, and China, forming a global PV so
Slide 20: CTS Key Business Updates (Cont'd)
CTS Key Business Updates (Cont’d) Decentralized Clinical Trials (”DCT”s) ⚫ Jointly published the “China DCT Industry Practice: 2023-2025 Three-Year Longitudinal Survey Report” with the China Society for Drug Regulation and Beijing Collaborative Medical Advance Center ⚫ Independently developed the SA
Slide 21: Business Updates: Clinical-related and Lab Services (CRLS)
03 Business Updates Clinical-related and Lab Services (“CRLS”) www.tigermedgrp.com
Slide 22: Clinical-related and Lab Services (CRLS)
Clinical-related and Lab Services (“CRLS”) Segment Revenue Gross Profit and Margin (RMB mm) (RMB mm) 36.1% 33.4% +8.6% +0.6% 1,934.2 1,780.9 642.8 646.4 1H2025 1H2026 1H2025 1H2026 22
Slide 23: Clinical-related and Lab Services (CRLS) (Cont'd)
Clinical-related and Lab Services (“CRLS”) (Cont’d) Status of partial business projects within the segment Data Management and Statistical Analysis Site Management Laboratory Services Completed 6,156 3,094 5,818 Completed 5,068 Completed 4,544 1,126 408 306 272 344 436 273 2023 2024 2025 06/30/2026
Slide 24: CRLS Key Business Updates
CRLS Key Business Updates Data Management & Statistical Analysis (“DMSA”) ⚫ In H1 2026, provided DMSA services for 4 approved Class I new drugs in China ⚫ As of June 30, 2026, global DMSA professionals exceeded 900 people, including a new DMSA team of over 20 people established in Malaysia in 2026 ⚫
Slide 25: CRLS Key Business Updates (Cont'd)
CRLS Key Business Updates (Cont’d) Site Management (“SMO”) ⚫ As of June 30, 2026, we had 3,094 ongoing SMO projects, up 25% YoY ⚫ In H1 2026, new bookings continued solid YoY growth; completed 154 projects in H1 2026 ⚫ As of June 30, 2026, total CRC headcount exceeded 4,000, covering 146 cities in C
Slide 26: Other Updates
04 Other Updates www.tigermedgrp.com
Slide 27: Updates of Investment Activities
Updates of Investment Activities Realized Investment Gain and Fair Value Gain(1) (RMB mm) ⚫ Portfolio included 214 companies in the healthcare 24.7 industry and 55 investment funds as of June 30, 2026 1H2025 1H2026 (45.7) ⚫ RMB 9.7 billion balance as of June 30, 2026 (89.6) ⚫ Invested RMB 414 millio
Slide 28: Employee Base
Employee Base The number of our employees increased to 11,984 as of June 30, 2026 from 11,130 as of Dec 31,2025 Employees Mix by Function (1) Employees Mix by Geography (1) Management and administration Overseas and Hong Kong China, Macao China, Taiwan China Marketing and 662 2,019 business developm
Slide 29: Appendix
05 Appendix www.tigermedgrp.com
Slide 30: Consolidated Statement of Profit or Loss
Consolidated Statement of Profit or Loss For the six months ended June For the six months ended June (RMB 000s) 30,2025 30,2026 I Total operating revenue 3,250,444 3,707,560 Including: Operating Revenue 3,250,444 3,707,560 II Total operating costs (2,942,263) (3,348,891) Including: Operating cost (2
Slide 31: Net profit attributable to shareholders after deducting extraordinary gain or loss
Net profit attributable to shareholders of the Company after deducting extraordinary gain or loss For the six months ended For the six months ended June (RMB 000s) June 30,2025 30,2026 Net profits attributable to shareholders of the Company 383,337 (413,159) Adjusted for: Loss/(gain) from disposal o
Slide 32: Consolidated Statement of Financial Position
Consolidated Statement of Financial Position (RMB 000s) As of December 31, 2025 As of June 30, 2026 NON-CURRENT ASSETS 22,181,598 21,284,861 Long-term equity investments 4,498,839 4,358,851 Other equity instrument investments 8,546 5,813 Other non-current financial assets 9,840,237 9,612,949 Investm
Slide 33: Consolidated Statement of Financial Position (Cont'd)
Consolidated Statement of Financial Position (Cont’d) (RMB 000s) As of December 31, 2025 As of June 30, 2026 CURRENT LIABILITIES 2,835,474 2,658,744 Short-term borrowings 511,021 245,645 Notes Payables 5,889 3,240 Accounts payables 365,229 317,521 Contract liabilities 1,079,155 1,354,710 Employee be
Slide 34: Hangzhou Tigermed Consulting Co., Ltd.
Hangzhou Tigermed Consulting Co., Ltd. 300347.SZ / 3347.HK August 2026 www.tigermedgrp.com
Hangzhou Tigermed Consulting — H1 2026 Earnings Presentation on 6ix